A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Myocardial infarction; Thrombosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PEGASUS; PEGASUS-TIMI 54
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Aug 2017 Results of a prospective economic substudy evaluating cost-effectiveness of ticagrelor + low-dose aspirin treatment published in the Journal of the American College of Cardiology
    • 16 Mar 2017 Results assessing platelet inhibition in the platelet function substudy(n=180), published in the Thrombosis and Haemostasis
    • 30 Jan 2017 Results (n=4426) assessing population pharmacokinetics of ticagrelor and AR-C124910XX, published in the International Journal of Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top